MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
4.810
-0.480
-9.07%
After Hours: 4.840 +0.03 +0.62% 19:59 04/03 EDT
OPEN
4.910
PREV CLOSE
5.29
HIGH
5.03
LOW
4.780
VOLUME
18.37M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
4.780
MARKET CAP
1.93B
P/E (TTM)
-2.8446
1D
5D
1M
3M
1Y
5Y
1D
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
The Motley Fool · 16h ago
Recursion Pharmaceuticals call volume above normal and directionally bullish
TipRanks · 1d ago
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
The Motley Fool · 3d ago
Weekly Report: what happened at RXRX last week (0324-0328)?
Weekly Report · 3d ago
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
The Motley Fool · 4d ago
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
The Motley Fool · 4d ago
Investors Look To Jobs Report For March As Conagra Brands, RH To Report Earnings
Seeking Alpha · 5d ago
Catalyst Watch: Tariff repercussions, Tesla deliveries, the jobs report, and Microsoft turns 50
Seeking Alpha · 6d ago
More
About RXRX
More
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Recently
Symbol
Price
%Change

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.